Boehringer Ingelheim signs Option to Acquire Trutino Biosciences
14.6.2022 19:00:00 EEST | Business Wire | Press release
Boehringer Ingelheim today announced the signing of an option to acquire Trutino Biosciences Inc. (the “Transaction”), a San Diego-based biotech company.
Trutino Biosciences is a pre-clinical stage biotech company dedicated to the discovery and development of next-generation cytokine therapies to treat immuno-oncology and autoimmune diseases. Boehringer Ingelheim is dedicated to a two-pronged research strategy to fight cancers: through cancer cell-directed and immune cell-targeting compounds. The ongoing research partnership between Boehringer Ingelheim and Trutino is part of an overarching effort to mobilize a patient’s immune system to fight cancer.
“Boehringer Ingelheim is excited to extend our partnership with Dr. Kim and his outstanding team at Trutino Biosciences. Our existing collaboration has made rapid and impressive progress in a short time frame, and we expect this field to have potential combination benefits with our existing immune-targeting assets,” said Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery Research, Boehringer Ingelheim. “The selective activation of specific cytokines localized in the tumor microenvironment holds enormous promise and has the potential to be a key element in fully harnessing the power of the immune system to fight cancer.”
“It's been two years since our initial strategic alliance began and we are very excited to further strengthen our partnership with Boehringer Ingelheim, a leader in cancer immunology, to advance potential cytokine therapeutic options that will transform the lives of cancer patients worldwide,” said Phillip Kim, Ph.D., MBA, Founder and CEO of Trutino Biosciences. “Boehringer Ingelheim has a deep commitment to our innovative scientific approaches and to bringing novel cancer therapies to patients. This global partnership validates the broad potential of our proprietary ‘On Demand Cytokine’ platform. As part of this expanded collaborative framework, we aim to rapidly develop a new generation of cytokine therapies as single agent and in combination with Boehringer Ingelheim's pipeline portfolio of cancer vaccines, oncolytic viruses, T cell engagers and other therapeutic modalities."
Under the agreement, Boehringer Ingelheim reserves the right to purchase all shares of Trutino Biosciences once specified program milestones have been achieved within a given timeframe. Until that time, Trutino will continue to operate as an independent company, with the existing fruitful strategic partnership and collaboration agreement between the companies continuing uninterrupted.
The transaction consideration consists of an option fee, the issuance of a convertible note and fixed purchase price terms to acquire Trutino Biosciences once pre-defined milestones are achieved. The option fee and principal amount of the convertible note funded by Boehringer Ingelheim at the signing of the option will collectively fully finance Trutino Biosciences through the next major development milestones of Trutino Biosciences.
Boehringer Ingelheim and Trutino Biosciences were introduced in 2019 during one of Boehringer Ingelheim’s “Grass Roots Innovation” events in San Diego. From there, in 2020 the companies forged a multi-target strategic partnership on conditionally masked cytokines. Boehringer Ingelheim’s Grass Roots programs provide biotech entrepreneurs mentoring and access to expertise and possible funding. To learn more, visit Grass Roots Innovation.
Please click on the link for "Notes to Editors":
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220614005761/en/
Contact information
Media Contacts
Boehringer Ingelheim
Reinhard Malin (CET time zone)
Innovation Unit/Bio Comms, Corp. Affairs
P: 49 6132 77-90815
reinhard.malin@boehringer-ingelheim.com
Linda Ruckel (EST time zone)
Innovation Unit/Bio Comms, Corp. Affairs
P: 1 203-791-6672
linda.ruckel@boehringer-ingelheim.com
Trutino Biosciences
Phillip Kim
+1 858-880-5501
pkim@trutinobio.com
John Zacamy
+1 212-486-2760
info@trutinobio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tourism Surges in Oulu as European Capital of Culture Year Drives Record Visitor Numbers and Major Exhibitions5.5.2026 15:23:00 EEST | Press release
The year has started strongly in Oulu, Finland, with tourism and cultural attendance rising across sectors. In January–February, total overnight stays increased by more than 20%, while February alone saw a 32% increase, reaching 78,400 stays. International tourism grew by over 40%. At the same time, the opening festival in January attracted around 250,000 visits, highlighting strong interest among both residents and visitors and signalling a promising year for the city’s tourism sector. “The start of the year has clearly shown the power of culture in strengthening tourism and regional vitality,” says Oulu2026 Programme Director Samu Forsblom. “With hundreds of cultural operators across all 39 municipalities involved, this is a unique year to visit our region in northern Finland.” A year of major exhibitions across the city Oulu’s exhibition programme extends beyond traditional museum spaces. Art appears in unexpected places such as a shopping centre, the city hall, a cathedral and in n
Bracco Launches BubbleGen™ Early Access Program for Microbubble-Based Cell Selection and Activation at ISCT5.5.2026 15:00:00 EEST | Press release
Bracco Imaging,a global pharmaceutical company that develops, manufactures, and markets innovative healthcare solutions, unveiled its Early Access Program today to enable cell therapy developers to evaluate the company’s new BubbleGen™ technology for cell therapy. Bracco’s team will be showcasing BubbleGen, which is designed to support a range of streamlined cell therapy manufacturing processes, at the International Society for Cell & Gene Therapy (ISCT) 2026 conference held this week in Dublin, Ireland. Through the BubbleGen evaluation kit, academic and industry researchers can explore a new approach to cell separation. The technology uses buoyant microbubbles to isolate specific cells, offering an alternative to traditional magnetic bead-based methods. The initial test case supports CD3+ T cell selection and activation in a format commonly used in commercial CAR T-cell therapies, and the platform is designed to extend beyond standard workflows. Researchers can adapt the system to iso
Fleet Launch Customer NetJets Takes Delivery of First Three Cessna Citation Ascend Midsize Business Jets5.5.2026 15:00:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, achieved a major milestone as the first three Cessna Citation Ascend business jets were delivered to fleet launch customer NetJets. NetJets, which operates the world's largest, most diverse private jet fleet, is the first private fleet operator to take delivery and begin operations with the Cessna Citation Ascend. Setting new standards in performance, comfort and operational efficiency for the midsize business jet market, the Citation Ascend builds on the longstanding relationship between Textron Aviation and NetJets by offering owners a seamless progression of advanced aircraft designed to deliver exceptional reliability, efficiency and luxury. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505495566/en/ Fleet launch customer NetJets takes delivery of first three Cessna Citation Ascend midsize business jets. (Photo Credit: Textron Aviation) “The Citation Ascend re
ATLAS Infrastructure Cornerstones United Utilities £800m Equity Placement5.5.2026 14:12:00 EEST | Press release
ATLAS Infrastructure (“ATLAS”) is a specialist Global Listed Infrastructure investor managing capital on behalf of its funds and long-term institutional clients. ATLAS has been an investor in UU since 2019 and, following the recent equity placement, ATLAS’s actively managed accounts hold a ~6.6% voting and economic interest in United Utilities plc (“UU”). ATLAS recognises the positive new direction established for the UK water sector and welcomes the opportunity to support UU management’s investment plan which will deliver the critical infrastructure required to support housing and industrial growth across North West England, as well as playing a crucial role in supporting nationally important initiatives related to AI data centres and sustainable energy. ATLAS strongly supports UU’s decision to raise new equity in order to accelerate its investment program through providing significant balance sheet capacity and financial flexibility through to the end of AMP8 in 2030. ATLAS values th
Jeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent5.5.2026 13:37:00 EEST | Press release
Jeito Capital (“Jeito”), a leading global independent private equity fund dedicated to Biopharma, today announces the appointments of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent. With extensive senior leadership experience across top-tier life-sciences investment funds, pharma and Biopharma companies, Elaine Caughey and Sarah Shackelton bring deep expertise in life sciences operations, investment, recruitment, and team building. Their appointments are synergistic and aligned with Jeito’s strategy, combining complementary skills across the full drug value chain to support portfolio company development and advance breakthrough therapies for patients. Building on a series of recent high-profile hires — including Samit Hirawat, M.D. as Strategic Medical Advisor, bringing senior leadership and clinical development experience at Novartis and Bristol Myers Squibb; Karin Van Baelen as Chief Regulatory Advisor, with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom